Figure 4.
Dopamine receptor antagonists suppressed wakefulness in mice with an absence of GABAergic neurons in the VMP. Total amount of wakefulness for 6 h in VGAT-CreDTA/VMP (A, C) or VGAT-CrehrGFP/VMP mice (B, D) treated with dopamine receptor antagonists (SCH23390 and/or raclopride; A, B) or the histamine H1 receptor antagonist ketotifen (C, D). Data are presented as the mean ± SEM (n = 5–8).